Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06UIS
|
|||
| Former ID |
DIB010621
|
|||
| Drug Name |
LY-2828360
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 2 | [1] | |
| Company |
Eli Lilly & Co
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 2 (CB2) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01319929) A Study of LY2828360 in Patients With Osteoarthritic Knee Pain. U.S. National Institutes of Health. | |||
| REF 2 | Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.